Sirolimus-associated hepatotoxicity: case report and review of the literature

Brock Macdonald
Evi Vakiani
Rhonda K Yantiss
Jun Lee
Robert S Brown Jr
Samuel H Sigal

1Division of Gastroenterology, Department of Medicine, University of California-San Francisco, San Francisco, CA; 2Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY; 3Department of Pathology and Laboratory Medicine, New York Weill Cornell Medical College, New York, NY; 4Division of Nephrology, Department of Medicine, Weill Cornell Medical College, New York, NY; 5Division of Gastroenterology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY; 6Division of Gastroenterology and Hepatology, Department of Medicine, New York University, New York, NY, USA

Correspondence: Samuel H Sigal
Division of Gastroenterology and Hepatology, Department of Medicine, New York University, 550 First Avenue, New York, NY 10016, USA
Tel +1 212 263 3643
Fax +1 212 263 3751
Email samuel.sigal@nyumc.org

Abstract: The use of sirolimus as an alternative to calcineurin inhibitors for posttransplant immunosuppression is associated with a variety of inflammatory conditions. In this report, we describe the case of a 34-year-old man who developed abnormal liver tests 6 years after live-donor kidney transplantation and 5 years after initiation of sirolimus-based immunosuppression. Elevated aminotransferase levels persisted after withdrawal of potentially hepatotoxic medications, and serologic evaluation for viral hepatitis, autoimmune disease, and genetic disorders was unrevealing. Liver biopsy revealed prominent hepatocellular injury associated with a mixed inflammatory infiltrate and liver tests normalized within 2 weeks of discontinuation of sirolimus. In this report, we review previous reports of sirolimus hepatotoxicity and propose a unifying hypothesis for the various inflammatory conditions that have been attributed to sirolimus.

Keywords: sirolimus, immunosuppression, transplant, inflammatory conditions, hepatotoxicity

Introduction

Kidney transplantation is associated with significantly decreased morbidity and mortality for patients with end-stage kidney disease on hemodialysis.1 The mainstay of posttransplant immunosuppression involves the use of the calcineurin inhibitors (CNIs) cyclosporine and tacrolimus. Sirolimus (SRL) (rapamycin, Rapamune™; Wyeth, Madison, NJ) is a macrocyclic lactone extracted from a soil sample from Easter Island and was initially developed as an antifungal agent.2 It was subsequently demonstrated to have potent immunosuppressant properties mediated by blockage of the mammalian target of rapamycin (mTOR), a protein kinase that regulates cell growth and cell cycle progression of B and T lymphocytes through signal transduction from the interleukin-2 receptor to the nucleus. Sirolimus is frequently utilized as an alternative to CNIs in cases of CNI-induced nephrotoxicity.3,4 With increasing SRL use, a variety of inflammatory extrarenal toxicities have been identified, including dermatologic, pulmonary and cardiac complications. In this report, we describe the histopathologic changes of SRL-associated hepatotoxicity and propose a unifying pathogenic mechanism for the various inflammatory conditions associated with its use.

Case report

A 34-year-old man with gout and hypertension presented with end-stage kidney disease at the age of 28 years. Kidney biopsy revealed changes consistent with chronic glomerulonephritis, and he underwent live donation kidney transplantation from his father in December 2002. Immediately following transplantation, immunosuppression
was achieved with tacrolimus and mycophenolate mofetil and the patient’s liver function tests were noted to be normal. However, 8 months after transplantation, the mycophenolate mofetil was discontinued and SRL therapy was begun. Mildly abnormal liver tests (alanine transaminase [ALT] 50 U/L [0–45 U/L]) were first noted 26 months after initiation of SRL in September 2005, and repeat liver tests 5 months later revealed further increases (aspartate aminotransferase [AST] 150 U/L [0–45 U/L]; ALT 161 U/L). Medications at that time included SRL, atorvastatin, ramipril, venlafaxine, and tacrolimus. The patient remained asymptomatic, and physical exam was unremarkable. Abdominal ultrasound 43 months after starting SRL revealed normal liver size and echogenicity, no biliary abnormalities, and patent hepatic vessels. Therapy with atorvastatin and venlafaxine were discontinued to exclude the possibility of drug-induced hepatotoxicity. Evaluations for viral hepatitis (hepatitis C virus antibody, hepatitis C virus RNA polymerase chain reaction [PCR], and hepatitis B virus DNA PCR) were negative. Abnormal liver tests persisted and repeated ultrasonographic imaging 51 months after starting SRL was again normal (Figure 1). One month later, a marked increase in aminotransferase levels (AST 669 U/L, ALT 868 U/L) was noted. Medications at that time included SRL, ramipril, tacrolimus, methylphenidate, and colchicine. Serologic evaluation was unremarkable (alpha-1 anti-trypsin, 181 mg/dL [93–224 mg/dL]; ceruloplasmin, 20 mg/dL [17–54 mg/dL]; iron and iron saturation, 81 mg/dL [50–160 mg/dL] and 26% [15%–53%], respectively; immunoglobulin M, 151 mg/dL [56–352 mg/dL]; immunoglobulin G, 1080 mg/dL [639–1349 mg/dL]). Antinuclear antibody; anti-smooth muscle antibody; antimitochondrial antibody; and PCR for cytomegalovirus, Epstein–Barr virus, herpes simplex virus, and varicella-zoster virus were negative. Abdominal magnetic resonance imaging revealed periportal edema, no biliary dilatation, and patent hepatic vessels. Abnormal liver tests persisted after discontinuing methylphenidate and colchicine.

Percutaneous liver biopsy revealed moderate to severe active hepatitis (Figure 2). The lymphocyte-rich inflammatory infiltrate also contained easily detectable Kupffer cells, plasma cells, eosinophils, and neutrophils, and was present in both portal tracts and lobules (Figure 3). Numerous necroinflammatory foci and necrotic hepatocytes were noted within the lobules (Figure 4). Mild cholestasis in combination with focal bile duct injury was also present (Figure 5), but steatosis, granulomas, and sinusoidal dilatation were lacking. A Masson’s trichrome stain demonstrated periportal and pericellular fibrosis, and moderate iron accumulation within Kupffer cells was revealed with a Prussian blue stain. SRL was discontinued with rapid and persistent normalization of AST and ALT levels within 2 weeks (Figure 1). Throughout this whole period the patient’s sirolimus levels remained
within the normal therapeutic range. His creatinine remained stable within normal limits.

**Discussion**

Hepatotoxicity is a potential but underrecognized complication of SRL immunosuppression in transplant recipients. Although hepatotoxicity is not listed as an indication for discontinuation of therapy, initial studies indicated that 5%–8% of renal allograft recipients developed elevated aminotransferase levels within the first 11 months of its administration. Among liver transplant recipients, SRL has been reported to be associated with a similar incidence of hepatotoxicity. In a single-center evaluation of 210 patients who received SRL-based immunosuppression, ten patients (4.7%) developed hepatotoxicity. In these cases, the initial rise in aminotransferase levels was attributed to rejection but increased SRL doses led to a further rise in levels. In liver allograft recipients, abnormal liver tests appeared to occur more rapidly than in kidney transplant patients at a mean of 21 days (range 7–40), suggesting either greater sensitivity of the liver allograft to the possible toxic effects of SRL or an increased vigilance of hepatologists in monitoring liver enzymes. In a subsequent investigation evaluating SRL-associated hepatotoxicity in renal transplant recipients, hepatotoxicity developed in 25% of patients with hepatitis B or C as compared with 8.3% without viral hepatitis. Although a statistical difference was not present, the study was limited by the inclusion of relatively few patients. In both the kidney and liver transplant recipients, however, prompt normalization of liver tests usually occurred within 3–4 weeks of discontinuation of SRL.

Reports of the histopathology of SRL hepatotoxicity are limited to a case report of a 30-year-old kidney transplant recipient who developed abnormal liver tests 16 months after transplantation.
after starting SRL and six cases in a series of liver transplant recipients.\textsuperscript{3,7} The liver biopsy findings of the renal transplant recipient included mild expansion of the portal tracts by lymphocytes with mild interface hepatitis and focal lobular inflammation.\textsuperscript{7} Liver biopsies performed in the six liver transplant recipients showed grade 2 inflammation in only one case.\textsuperscript{4} Histologic changes consistent with sinusoidal congestion were observed in two patients, while one biopsy showed eosinophilia.\textsuperscript{4}

The hepatitis in our case can be attributed to SRL-associated hepatotoxicity due to the exclusion of other causes, onset after initiation of SRL therapy, and prompt resolution after its withdrawal. Other potential hepatotoxic agents were withdrawn without improvement in liver tests, and other causes of liver disease including viral, metabolic, and genetic were excluded. For definite determination of the role SRL as the offending agent, rechallenge with SRL would have been required. However, this was deemed not to be appropriate given the presumptive diagnosis with prompt normalization aminotransferase levels after withdrawal and the ready availability of an alternative immunosuppressive agent.

Our case represents the most complete report of the histopathology of SRL-associated hepatotoxicity to date. In the previous case reports, histopathological details were scant.\textsuperscript{3,4,7} In the series of the liver transplant recipients with abnormal liver tests on SRL, potential concomitant processes of rejection and/or viral hepatitis prevent an absolute determination of the contribution of SRL to the histopathology.

The hepatitis in our case can be attributed to SRL-associated hepatotoxicity due to the exclusion of other causes, onset after initiation of SRL therapy, and prompt resolution after its withdrawal. Other potential hepatotoxic agents were withdrawn without improvement in liver tests, and other causes of liver disease including viral, metabolic, and genetic were excluded. For definite determination of the role SRL as the offending agent, rechallenge with SRL would have been required. However, this was deemed not to be appropriate given the presumptive diagnosis with prompt normalization aminotransferase levels after withdrawal and the ready availability of an alternative immunosuppressive agent.

The liver biopsy in our patient showed significantly higher inflammation and hepatocellular damage compared to previous reported cases of SRL-associated hepatotoxicity, mirroring the higher elevation in aminotransferase levels seen in our case.\textsuperscript{3,4,7} These findings could be due to the prolonged duration of SRL use after the onset of hepatotoxicity. Similarly, it was noted that increased doses of SRL resulted in higher aminotransferase levels in liver transplant recipients, suggesting a possible dose-dependent relationship.

Although the exact mechanism of SRL-induced injury remains to be determined, the presence of plasma cells and eosinophils suggest an underlying immune-mediated process. In support of this proposal, the pathology of SRL-hepatotoxicity is similar to that of other forms of SRL-induced inflammatory toxicities, including leukocytoclastic vasculitis, interstitial pneumonitis, bronchiolitis obliterans organizing pneumonia, diffuse alveolar hemorrhage, pericarditis, and mucositis.\textsuperscript{8–13} In addition, the clinical response of SRL-induced oral aphthous ulcers to the topical application of the potent steroid clobetasol suggests a similar immune-mediated pathologic process.\textsuperscript{9} Mechanisms that have been proposed for SRL-induced immune-mediated pulmonary toxicity include SRL-associated exposure of cryptic alveolar antigens and hapten formation between SRL and high-affinity plasma proteins that induces Th-1 activation and cytokine release.\textsuperscript{14,15} The inflammatory infiltrate present in our case suggests a possible similar mechanism of immune activation within the liver.

The paucity of significant fibrosis in our case is a striking finding given the prolonged injury of over 2 years with significant inflammation and marked aminotransferase elevation. Clinically, this effect is associated with impaired wound healing in the early posttransplant period.\textsuperscript{16–18} SRL has been shown to inhibit wound healing, possibly by the inhibition of platelet-derived growth factor, which activates fibroblasts. As well, there appears to be decreased angiogenesis due to a decrease of endothelial expressed vascular endothelial growth factor receptors.\textsuperscript{16} In the liver, SRL inhibits de novo fibrinogenesis by decreasing the activity of stellate cells, which are the primary source of fibrin deposition.\textsuperscript{16,17}

Although speculative, we propose that these unique properties account for the limited fibrosis in both SRL-associated hepatic and pulmonary toxicity.\textsuperscript{15,18} In addition, activation of mTOR receptor by SRL, which inhibits autophagy, may play a further role in the pathogenesis of SRL-associated drug toxicity and contribute to the especially prominent number of apoptic bodies observed in our case.

SRL is an important addition to the armamentarium of posttransplant immunosuppression and is frequently employed for prevention of calcineurin-associated nephrotoxicity.\textsuperscript{3} With the widespread use of SRL, however, an increasing number of potential toxicities have been identified. Our case emphasizes the need to include hepatotoxicity in the differential diagnosis of abnormal liver tests in the posttransplant patient on SRL. An increased awareness of the potential for SRL-associated hepatotoxicity is particularly important in the management of liver transplant recipients with chronic hepatitis in whom abnormal liver tests are common.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


